Computational procedure for determining physicochemical properties of doxorubicin- PLGA nanoparticles and daunorubicin-PLGA nanoparticles

International Journal of PharmTech Research

Volumn 4, Issue 3, 2012, Pages 1242-1246

  Hassani, S M ^a   Bagheri, S ^b  

^a ISLAMIC AZAD UNIVERSITY   (Iran)

^b ISLAMIC AZAD UNIVERSITY   (Iran)

Author keywords

Anti cancer drugs; Daunorubicin; Doxorubicin; Molecular geometry; PLGA nanoparticles

Indexed keywords

DAUNORUBICIN; DOXORUBICIN; NANOPARTICLE; POLYGLACTIN;

ARTICLE; DENSITY FUNCTIONAL THEORY; DIPOLE; HARTREE FOCK CALCULATION; LIPOPHILICITY; MATHEMATICAL ANALYSIS; PHYSICAL CHEMISTRY; SOLVATION;

EID: 84870228943     PISSN: 09744304     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Di Macro A, Arcamone F, Zunino F, Daunomycin (daunorubicin) and adriamycin and structural analogues, Biological activity and mechanism of action antimicrobial and antitumor agents, Springer Verlag, Berlin, 1975, 101-128.
2. Neidle S, The molecular basis for the action of some DNA binding drugs, Prog. Med. Chem, 1979, 16, 151-221.
3. Crooke S. T, Reich S. D, Anthracylines current status and new developments, Academic Press, New York, 1980, 61.
4. Viswamitra M. A, Kennard O, Jones P. G, Sheldrick G. M, Salisbury S, Falvello L, Shakked Z, DNA double helical fragment at atomic resolution, Nature, 1978, 273, 687-688.
5. Manfait M, Alix A. J, Jeannesson P, Jardillier J. C, Theophanides T, Interaction of adriamycin with DNA as studied by resonance Raman spectroscopy, Nucleic Acids Res, 1982, 10, 3803-3816.
6. Hande K. R, clinical applications of anticancer drugs targeted to topoisomeraseII, Biochim. Biophy. Acta, 1998, 1400, 173-84.
7. Dancey J, Eisenhauer E. A, current perspectives on camptothecins in cancer treatment, Br. J. Cancer, 1996, 74, 327-338.
8. Harrison M, Tomlinson D, Stewart S, liposomal entrapped doxorubicin an active agent in AIDS-related kaposi's sarcoma, J. clin. Oncol, 1995, 13, 914-20.
9. Porzolt F, Kreuser E. D, Meuret G, Mende S, Buchelt L, Redenbacher M, Heissmeyer H. H, Strigl P, Hiemeyer V, Krause H. H, Fleischer K, Saurnweber G, Leichtle R, Matischok B, Gaus W, Heimple H, High intensity therapy versus low intensity therapy in advanced breast cancer patients, Cancer Treat. Rev, 1990, 17, 287-92.
10. Kushwaha P. S, Mishra P. C, Molecular electrostatic potential maps of the anti cancer drugs daunomycin and adriamycin an ab initio theoretical study, J. Mol. Struct, 2003, 636, 149-156.
11. Berman E, Heller G, Santorsa J, McKenzie S, Gee T. S, Kempin S, Gulati S, Andreeff M, Kolitz J, Gabrilove J, Reich L, Mayer K, Keefe D, Trainor K, Schluger A, Penenberg D, Raymond V, Oreilly R, Jhanwar S, Young C, Clarkson B, Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adault patients with newly diagnosed acute myelogenous leukemia, Blood, 1991, 77, 1666.
12. Sidney Farber MD, Chemotherapy in the Treatment of Leukemia and Wilms Tumor, JAMA, 1966, 198, 826-836.
13. Arcamone F, Doxorubicin anticancer antibiotics Medicinal Chemistry a series of medicinal chemistry, Academic Press, New york, 1981, 17.
14. Saltzman W. M, Drug delivery engineering principles for drug therapy, Oxford University Press, 2001, 6.
15. Duncan R, The drawing era of polymer therapeutics, Nat. Rev. Drug Discov, 2003, 2, 347-360.
16. Kopeček J, Kopečková P, Minko T, Lu Z. R, Peterson C. M, Water soluble polymers in tumor targeted delivery, J. control. Release, 2001, 74, 147-158.
17. Bagheri S, Chamani Z, Hassani S. M, A computational study o physicochemical and geometrical properties of daunorubicin-GA3 daunorubicin-mGA3 Dox-GA3 an Dox-mGA3, Int. J. ChemTech Res, 2012, 4. 144.
18. Chahremani H, Hassani S. M, A study on the geometrical and physicochemical properties of daidzen daunomycin conjugate using density functional theory and Hartree Fock, Int. J. PharmTech Res, 2012, 4, 148.
19. Yoo H. S, Lee K. H, Oh J. E, Park T. G, In vitro and vivo anti tumor activities of nanoparticles based on doxorubicin PLGA conjugates, J. Control Release, 2000, 68, 419-431.
20. Frisch M. J, Trucks G. W, Schlegel H. B, Scuseria G. E, Robb M. A, Cheeseman J. R, Montgomery J. R, Vreven T, Kudin K. N, Burant J. C, Millam J. M, Iyengar S. S, Tomasi J, Barone V, Mennucci B, Cossi M, Scalmani G, Rega N, Petersson G. A, Nakatsuji H, Hada M, Ehara M, Toyota K, Fukuda R, Hasegawa J, Ishida M, Nakajima T, Honda Y, Kitao O, Nakai H, Klene M, Li X, Knox J. E, Hratchian H. P, Cross J. B, Bakken V, Adamo C, Jaramillo J, Gomperts R, Stratmann R. E, Yazyev O, Austin A. J, Cammi R, Pomelli C, Ochterski J. W, Ayala P. Y, Morokuma K, Voth G. A, Salvador P, Dannenberg J. J, Zakrzewski V. G, Dapprich S, Daniels A. D, Strain M. C, Farkas O, Malick D. K, Rabuck A. D, Raghavachari K, Foresman J. B, Ortiz J. V, Cui Q, Baboul A. G, Clifford S, Cioslowski J, Stefanov B. B, Liu G, Liashenko A, Piskorz P, Komaromi I, Martin R. L, Fox J. D, Keith T, Al-laham M. A, Peng C. Y, Nanayakkara A, Challacombe M, Gill P. M. W, Johnson B, Chen W, M. w, Gonzalez C, Pople J. A, Gaussian 03, Revision B. 03, Gaussian, Inc, Wallingford CT, 2004.
21. Srinophakun T, Boonmee J, Preliminary study of conformation and drug release mechanism of doxorubicin conjugated glycol chitosan via cis- Aconityl linkage by molecular modeling, Int. J. Mol. Sci, 2011, 12, 1672-1683.
22. Hassani S. M, Ghahremani H, Bagheri S, The estimation of the solubility of daidzein adriamycin conjugate and adriamycin based on density functional theory and Hartree-Fock studies, Scholars Research Library, 2011, 3, 296-300.
23. www.Hyperchem.com.